Table 7 Clinicians were positive about the role of ataluren in the treatment of patients with nmDMD
Theme | Statement | Overall Agreement | Consensus |
|---|---|---|---|
Ataluren | Ataluren is generally well tolerated | 100.0% | Very high |
Ataluren (in addition to standard of care) delays disease progression in patients with nmDMD | 100.0% | Very high | |
Patients receiving treatment with ataluren appear to have more energy | 95.0% | Very high | |
Patients receiving treatment with ataluren seem to better manage daily situations | 90.0% | High | |
Patients receiving treatment with ataluren appear to have a better overall quality of life | 95.0% | Very high | |
Ataluren (in addition to standard of care) significantly delays the decline in muscle function in patients with nmDMD | 75.0% | High |